comparemela.com

Latest Breaking News On - Bladder cancer disease team - Page 1 : comparemela.com

DFF332 Elicits Efficacy and Is Safe in Advanced Clear Cell RCC

The small molecule inhibitor DFF332 elicited clinical activity and had a tolerable safety profile in patients with advanced clear cell renal cell carcinoma.

United statesSumanta kumar palBladder cancer disease teamKidney cancer programDatabase consortiumInternational metastaticMedical oncologyTherapeutics researchHope comprehensive cancer center

Dr Pal Previews ASCO 2024 Data in Renal Cell Carcinoma

Sumanta Kumar Pal, MD, FASCO, discusses key biomarker analyses in renal cell carcinoma that will be presented at the 2024 ASCO Annual Meeting.

Sumanta kumar palKidney cancer programTherapeutics researchDepartment of medical oncologyBladder cancer disease teamMedical oncology

Dr Pal on the Rationale for Investigating Zanzalintinib in Relapsed/Refractory ccRCC

Sumanta Kumar Pal, MD, FASCO, chair, discusses the rationale for treating patients with zanzalintinib in relapsed/refractory clear cell renal cell carcinoma.

Sumanta kumar palBladder cancer disease teamDepartment of medical oncologyKidney cancer programInternational kidney cancer symposiumTherapeutics researchMedical oncologyKidney cancer symposiumCity of hopeOnclive tvGenitourinary cancers

Dr Pal on Outcomes With the Use of Zanzalintinib in Relapsed/Refractory ccRCC

Sumanta Kumar Pal, MD, FASCO, discusses outcomes with the use of zanzalintinib in patients with relapsed/refractory clear cell renal cell carcinoma.

Sumanta kumar palTherapeutics researchBladder cancer disease teamKidney cancer programInternational kidney cancer symposiumDepartment of medical oncologyMedical oncologyKidney cancer symposiumOnclive tvGenitourinary cancersClear cell renal carcinoma

vimarsana © 2020. All Rights Reserved.